Baidu
map

Cancer Cell:阻断肿瘤细胞“微环境”抵御白血病恶化

2015-06-11 佚名 生物谷

刊登在国际杂志Cancer Cell上的一篇研究论文中,来自纽约大学医学中心(NYU Langone Medical Center)等处的研究人员通过研究揭示了一项在抵御恶性白血病上的重大研究突破,这或为开发治疗白血病的新型靶向疗法提供一定的帮助,相关研究发表于国际杂志Cancer Cell上。 文章中研究者通过阻断急性T淋巴细胞母细胞白血病(T-ALL)核心中T细胞表面的特殊蛋白受体的活性,从

刊登在国际杂志Cancer Cell上的一篇研究论文中,来自纽约大学医学中心(NYU Langone Medical Center)等处的研究人员通过研究揭示了一项在抵御恶性白血病上的重大研究突破,这或为开发治疗白血病的新型靶向疗法提供一定的帮助,相关研究发表于国际杂志Cancer Cell上。

文章中研究者通过阻断急性T淋巴细胞母细胞白血病(T-ALL)核心中T细胞表面的特殊蛋白受体的活性,从而成功地抑制并且逆转了T-ALL的特殊癌性白细胞的生长。对小鼠和人类细胞进行试验,研究者发现,阻断名为CXCR4的特殊分子就可以在两周内抑制骨髓和脾脏组织中疾病的进展,而CXCR4是一种特殊的归巢受体蛋白分子,其可以帮助T细胞成熟并且将血细胞吸引到骨髓中;而该实验可以使得实验活老鼠机体中的白细胞至少超过30周时间免于癌变,进一步对发展为T-ALL的小鼠进行研究发现,剔除CXCR4所结合的蛋白CXCL12或许也可以阻断T-ALL的进展。

研究者Susan Schwab博士说道,本文研究首次发现,CXCR4信号对于急性T淋巴细胞母细胞白血病的细胞生长和疾病发展非常必要;而我们的实验则发现阻断CXCR4就可以摧毁白血病细胞。目前研究者制定了很多试验计划来寻找CXCR4的拮抗剂,而且研究者希望更多的是结合当前已经建立的化疗体系来进行寻找;抗CXCR4的药物目前正在初步试验阶段,用以治疗特定类型的髓样白血病,而且截至目前这种药物的耐药性较好,但目前却并没有应用于治疗T-ALL中。

T-ALL是一种尤为特殊的恶性白血病,因为并没有许多疗法进行选择,一项针对美国人的调查结果发现,使用标准化疗药物未能缓解患者的疾病后,仅有23%的患者的存活期超过了5年。而研究者也指出,靶向作用及破坏白血病细胞微环境的药物或许可以帮助有效抵御白血病的发展。

开启白血病的细胞通常会在CXCL12产生的血管附近的骨髓中集聚,而文章中研究者调查了CXCR4的表达和功能,由于其会结合CXCL12,随后研究者就确定了CXCR4-CXCL12分子信号在白血病发展中的关键角色,后期研究中研究者还需要更多深入的研究来阐明CXCR4促进并且维持T-ALL发生的机制。

这项研究中,研究者剔除了白血病小鼠机体骨髓血管中产生的CXCL12蛋白,随后就发现骨髓中疾病的发展在三周内停止了,而且相比维持CXCL12持续产生的小鼠而言,剔除CXCL12蛋白的小鼠机体中的肿瘤明显变小了。CXCR4基因的剔除会使得持续性的T-ALL出现缓解,同似乎也会促进癌变血细胞从骨髓中清除。

最后研究者表示,将数百万人类T-ALL细胞移植入正常小鼠机体中,随后利用抗CXCR4药物进行治疗来诱导疾病在两周内缓解,结果显示,病变的脾脏和骨髓组织几乎可以恢复到正常水平;后期研究者还将通过进行更多的研究来阐明肿瘤细胞微环境对于开发治疗白血病的关键作用,也为阐明白血病的发病机制提供一定的思路。

原始出处:

Lauren A. Pitt8, Anastasia N. Tikhonova8, Hai Hu, Thomas Trimarchi, Bryan King, Yixiao Gong, Marta Sanchez-Martin, Aris Tsirigos, Dan R. Littman, Adolfo A. Ferrando, Sean J. Morrison, David R. Fooksman9, Iannis Aifantis9correspondenceemail, Susan R. Schwab.CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance.Cancer Cell.June 8, 2015, 27(6):755-768.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869137, encodeId=319e186913ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 17 13:00:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710010, encodeId=38bf1e10010c5, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Sep 30 08:00:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959391, encodeId=445a195939118, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Feb 26 22:00:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780655, encodeId=ca901e80655ba, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Oct 23 05:00:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29549, encodeId=6c9c295499b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:40:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312915, encodeId=780f1312915ca, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Jun 13 00:00:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27042, encodeId=f0f62e042a5, content=有新的盼头, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:41:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27015, encodeId=c4e72e0156c, content=微环境+恶性细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Thu Jun 11 15:12:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869137, encodeId=319e186913ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 17 13:00:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710010, encodeId=38bf1e10010c5, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Sep 30 08:00:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959391, encodeId=445a195939118, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Feb 26 22:00:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780655, encodeId=ca901e80655ba, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Oct 23 05:00:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29549, encodeId=6c9c295499b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:40:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312915, encodeId=780f1312915ca, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Jun 13 00:00:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27042, encodeId=f0f62e042a5, content=有新的盼头, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:41:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27015, encodeId=c4e72e0156c, content=微环境+恶性细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Thu Jun 11 15:12:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869137, encodeId=319e186913ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 17 13:00:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710010, encodeId=38bf1e10010c5, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Sep 30 08:00:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959391, encodeId=445a195939118, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Feb 26 22:00:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780655, encodeId=ca901e80655ba, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Oct 23 05:00:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29549, encodeId=6c9c295499b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:40:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312915, encodeId=780f1312915ca, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Jun 13 00:00:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27042, encodeId=f0f62e042a5, content=有新的盼头, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:41:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27015, encodeId=c4e72e0156c, content=微环境+恶性细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Thu Jun 11 15:12:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2016-02-26 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869137, encodeId=319e186913ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 17 13:00:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710010, encodeId=38bf1e10010c5, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Sep 30 08:00:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959391, encodeId=445a195939118, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Feb 26 22:00:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780655, encodeId=ca901e80655ba, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Oct 23 05:00:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29549, encodeId=6c9c295499b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:40:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312915, encodeId=780f1312915ca, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Jun 13 00:00:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27042, encodeId=f0f62e042a5, content=有新的盼头, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:41:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27015, encodeId=c4e72e0156c, content=微环境+恶性细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Thu Jun 11 15:12:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869137, encodeId=319e186913ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 17 13:00:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710010, encodeId=38bf1e10010c5, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Sep 30 08:00:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959391, encodeId=445a195939118, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Feb 26 22:00:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780655, encodeId=ca901e80655ba, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Oct 23 05:00:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29549, encodeId=6c9c295499b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:40:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312915, encodeId=780f1312915ca, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Jun 13 00:00:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27042, encodeId=f0f62e042a5, content=有新的盼头, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:41:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27015, encodeId=c4e72e0156c, content=微环境+恶性细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Thu Jun 11 15:12:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-26 huaxipanxing

    看看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1869137, encodeId=319e186913ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 17 13:00:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710010, encodeId=38bf1e10010c5, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Sep 30 08:00:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959391, encodeId=445a195939118, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Feb 26 22:00:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780655, encodeId=ca901e80655ba, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Oct 23 05:00:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29549, encodeId=6c9c295499b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:40:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312915, encodeId=780f1312915ca, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Jun 13 00:00:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27042, encodeId=f0f62e042a5, content=有新的盼头, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:41:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27015, encodeId=c4e72e0156c, content=微环境+恶性细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Thu Jun 11 15:12:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1869137, encodeId=319e186913ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 17 13:00:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710010, encodeId=38bf1e10010c5, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Sep 30 08:00:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959391, encodeId=445a195939118, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Feb 26 22:00:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780655, encodeId=ca901e80655ba, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Oct 23 05:00:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29549, encodeId=6c9c295499b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:40:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312915, encodeId=780f1312915ca, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Jun 13 00:00:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27042, encodeId=f0f62e042a5, content=有新的盼头, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:41:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27015, encodeId=c4e72e0156c, content=微环境+恶性细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Thu Jun 11 15:12:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 qinweihan19

    有新的盼头

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1869137, encodeId=319e186913ed9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Feb 17 13:00:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710010, encodeId=38bf1e10010c5, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Sep 30 08:00:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959391, encodeId=445a195939118, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Feb 26 22:00:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780655, encodeId=ca901e80655ba, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Oct 23 05:00:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29549, encodeId=6c9c295499b, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Fri Jun 26 12:40:00 CST 2015, time=2015-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312915, encodeId=780f1312915ca, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat Jun 13 00:00:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27042, encodeId=f0f62e042a5, content=有新的盼头, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:41:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27015, encodeId=c4e72e0156c, content=微环境+恶性细胞, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Thu Jun 11 15:12:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 medcardio

    微环境+恶性细胞

    0

相关资讯

艾伯维治疗白血病新药venetoclax获FDA突破性药物认证

艾伯维公司最近宣布公司开发的治疗白血病新药venetoclax获得了FDA的突破性药物认证。FDA认为这种药物在治疗带有17p基因缺失突变的慢性粒细胞白血病患者方面有着显著疗效。数据显示,目前约有3%-10%的一线慢性粒细胞白血病患者都带有这种基因突变,而在出现抗药性的慢性白血病患者中,这一比例更是高达50%之多。 在去年年底召开的美国血液学会年会(ASH)上,venetoclax就曾以其出色的

Nat Immunol:儿童接种疫苗降低白血病发病风险?

加州大学旧金山分校的研究人员发现,一种常规接种的疫苗能够预防急性淋巴细胞白血病(ALL)这一最常见的儿童癌症。该项研究成果发表在最新一期Nature Immunology杂志上。根据国家癌症协会的数据,b型流感嗜血杆菌(Hib)疫苗不仅可以防止耳朵感染和Hib所引起的脑膜炎,而且能够预防ALL,后者占15岁以下儿童癌症诊断中的大约25%。Hib疫苗是美国疾病控制中心标准推荐的疫苗接种计划的一部分,

ASCO 2015:年度“颁奖盛典”

1月20日,美国临床肿瘤学会(ASCO)在《临床肿瘤学杂志》(JClin Oncol)上在线发布了《ASCO年度报告:2015临床肿瘤学进展》,不仅保持了以往传统,对上一年的癌症预防、治疗和患者照护有重大影响的临床进展进行探讨,而且还首次发布ASCO年度进展(AdvanceoftheYear)。 年度进展 ASCO年度报告首次发布年度进展(Advanceof the

揭秘上海科技**奖:女科学家用砒霜“以毒攻毒”治愈白血病

2014年度上海市科学技术奖共授奖287项(人)。授予26项成果自然科学奖。其中,由上海交通大学医学院附属瑞金医院陈赛娟团队完成的“髓系白血病发病机制和新型靶向治疗研究”项目荣获自然科学奖特等奖,这是2012年上海科技奖励设立特等奖以来的第二个特等奖,也是自然科学奖领域出现的第一个特等奖。 一袭白大褂,身形娇小的陈赛娟院士气质温婉、平和。并没有想象中学科领头人的“强悍”气场。甚至,接受媒体记

JAMA Pediatr:母乳喂养或可明显降低儿童患白血病的风险

 据统计,全球每年有大约175000名十五岁以下儿童被确诊为癌症。在发达国家中,每年的发病率增长大约0.9%,而这一结果被部分解释为诊断和报道的技术进步。儿童癌症是较少见的,并且过去数年中存活率也大为提高,这要归功于治疗技术的进步。但是,这仍旧是发达国家中儿童和青少年的首要致死因素。白血病是儿童癌症中最为常见的一种,30%的儿童癌症是白血病。儿童最为常见的两种急性白血病是急性淋巴细胞白血

Mol Cancer:科学家发现治疗急性髓性白血病的新靶点

在白血病细胞中发现的长链非编码RNA(lncRNA)或许会影响酪氨酸激酶靶向白血病疗法的疗效,而目前lncRNA CCDC26的功能并没有被完全解析,而来自广岛大学的研究者则在杂志Molecular Cancer上刊登了他们的最新研究成果,研究者在文章中揭示了CCDC26控制受体酪氨酸激酶KIT表达的机制,相关研究结果或为理解白血病的复发且帮助开发白血病疗法提供一定的帮助。近来转录组学的相关研究发

Baidu
map
Baidu
map
Baidu
map